These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 7914668

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of congenital hyperammonemia on the cerebral and hepatic levels of the intermediates of energy metabolism in spf mice.
    Ratnakumari L, Qureshi IA, Butterworth RF.
    Biochem Biophys Res Commun; 1992 Apr 30; 184(2):746-51. PubMed ID: 1575747
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evidence for cholinergic neuronal loss in brain in congenital ornithine transcarbamylase deficiency.
    Ratnakumari L, Qureshi IA, Butterworth RF.
    Neurosci Lett; 1994 Aug 29; 178(1):63-5. PubMed ID: 7816342
    [Abstract] [Full Text] [Related]

  • 5. Effect of sodium benzoate on cerebral and hepatic energy metabolites in spf mice with congenital hyperammonemia.
    Ratnakumari L, Qureshi IA, Butterworth RF.
    Biochem Pharmacol; 1993 Jan 07; 45(1):137-46. PubMed ID: 8424807
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Developmental study of hepatic glutamine synthetase in a mouse model of congenital hyperammonemia.
    Skarpetas A, Mawal Y, Qureshi IA.
    Biochem Mol Biol Int; 1997 Sep 07; 43(1):133-9. PubMed ID: 9315291
    [Abstract] [Full Text] [Related]

  • 8. Reduction in the MK-801 binding sites of the NMDA sub-type of glutamate receptor in a mouse model of congenital hyperammonemia: prevention by acetyl-L-carnitine.
    Rao KV, Qureshi IA.
    Neuropharmacology; 1999 Mar 07; 38(3):383-94. PubMed ID: 10219976
    [Abstract] [Full Text] [Related]

  • 9. Aberrations of ammonia metabolism in ornithine carbamoyltransferase-deficient spf-ash mice and their prevention by treatment with urea cycle intermediate amino acids and an ornithine aminotransferase inactivator.
    Li MX, Nakajima T, Fukushige T, Kobayashi K, Seiler N, Saheki T.
    Biochim Biophys Acta; 1999 Sep 20; 1455(1):1-11. PubMed ID: 10524224
    [Abstract] [Full Text] [Related]

  • 10. Efficient mitochondrial import of newly synthesized ornithine transcarbamylase (OTC) and correction of secondary metabolic alterations in spf(ash) mice following gene therapy of OTC deficiency.
    Zimmer KP, Bendiks M, Mori M, Kominami E, Robinson MB, Ye X, Wilson JM.
    Mol Med; 1999 Apr 20; 5(4):244-53. PubMed ID: 10448647
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ornithine transcarbamylase deficiency: pathogenesis of the cerebral disorder and new prospects for therapy.
    Michalak A, Butterworth RF.
    Metab Brain Dis; 1997 Sep 20; 12(3):171-82. PubMed ID: 9346466
    [Abstract] [Full Text] [Related]

  • 13. [Brain monoamines and behavior in hyperammonemic sparse-fur mice].
    Minakami K.
    Nihon Yakurigaku Zasshi; 1994 May 20; 103(5):219-29. PubMed ID: 8188118
    [Abstract] [Full Text] [Related]

  • 14. Loss of [3H]MK801 binding sites in brain in congenital ornithine transcarbamylase deficiency.
    Ratnakumari L, Qureshi IA, Butterworth RF.
    Metab Brain Dis; 1995 Sep 20; 10(3):249-55. PubMed ID: 8830285
    [Abstract] [Full Text] [Related]

  • 15. Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency.
    Imoto K, Tanaka M, Goya T, Aoyagi T, Takahashi M, Kurokawa M, Tashiro S, Kato M, Kohjima M, Ogawa Y.
    BMC Gastroenterol; 2022 Mar 28; 22(1):144. PubMed ID: 35346058
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ornithine restores ureagenesis capacity and mitigates hyperammonemia in Otc(spf-ash) mice.
    Marini JC, Lee B, Garlick PJ.
    J Nutr; 2006 Jul 28; 136(7):1834-8. PubMed ID: 16772445
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The sparse fur mouse as a model for gene therapy in ornithine carbamoyltransferase deficiency.
    Batshaw ML, Yudkoff M, McLaughlin BA, Gorry E, Anegawa NJ, Smith IA, Hyman SL, Robinson MB.
    Gene Ther; 1995 Dec 28; 2(10):743-9. PubMed ID: 8750014
    [Abstract] [Full Text] [Related]

  • 20. Reduced ornithine transcarbamylase activity does not impair ureagenesis in Otc(spf-ash) mice.
    Marini JC, Lee B, Garlick PJ.
    J Nutr; 2006 Apr 28; 136(4):1017-20. PubMed ID: 16549467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.